RMD Open (May 2024)

Predictive utility of ANCA positivity and antigen specificity in the assessment of kidney disease in paediatric-onset small vessel vasculitis

  • Dirk Foell,
  • Adam Huber,
  • Linda Wagner-Weiner,
  • Susan Shenoi,
  • Vidya Sivaraman,
  • Sirirat Charuvanij,
  • Jeffrey N Bone,
  • David A Cabral,
  • Paul Dancey,
  • Susanne Benseler,
  • Flora Mcerlane,
  • Marek Böhm,
  • Neil Martin,
  • Phil Riley,
  • Roberta Berard,
  • Rae Yeung,
  • Eslam Al-Abadi,
  • Alan Rosenberg,
  • Kamran Mahmood,
  • Else S Bosman,
  • Simranpreet K Mann,
  • Kimberly A Morishita,
  • Kelly L Brown,
  • Melissa Elder,
  • Stacey Tarvin,
  • Kathryn Cook,
  • Karen James

DOI
https://doi.org/10.1136/rmdopen-2024-004315
Journal volume & issue
Vol. 10, no. 2

Abstract

Read online

Objectives The objective of this study is to evaluate whether anti-neutrophil cytoplasmic antibody (ANCA) seropositivity and antigen specificity at diagnosis have predictive utility in paediatric-onset small vessel vasculitis.Methods Children and adolescents with small vessel vasculitis (n=406) stratified according to the absence (n=41) or presence of ANCA for myeloperoxidase (MPO) (n=129) and proteinase-3 (PR3) (n=236) were compared for overall and kidney-specific disease activity at diagnosis and outcomes between 1 and 2 years using retrospective clinical data from the ARChiVe/Paediatric Vasculitis Initiative registry to fit generalised linear models.Results Overall disease activity at diagnosis was higher in PR3-ANCA and MPO-ANCA-seropositive individuals compared with ANCA-negative vasculitis. By 1 year, there were no significant differences, based on ANCA positivity or specificity, in the likelihood of achieving inactive disease (~68%), experiencing improvement (≥87%) or acquiring damage (~58%). Similarly, and in contrast to adult-onset ANCA-associated vasculitis, there were no significant differences in the likelihood of having a relapse (~11%) between 1 and 2 years after diagnosis. Relative to PR3-ANCA, MPO-ANCA seropositivity was associated with a higher likelihood of kidney involvement (OR 2.4, 95% CI 1.3 to 4.7, p=0.008) and severe kidney dysfunction (Kidney Disease Improving Global Outcomes (KDIGO) stages 4–5; OR 6.04, 95% CI 2.77 to 13.57, p<0.001) at onset. Nonetheless, MPO-ANCA seropositive individuals were more likely to demonstrate improvement in kidney function (improved KDIGO category) within 1 year of diagnosis than PR3-ANCA seropositive individuals with similarly severe kidney disease at onset (p<0.001).Conclusions The results of this study suggest important paediatric-specific differences in the predictive value of ANCA compared with adult patients that should be considered when making treatment decisions in this population.